Diagonal Bio AB (publ), 559248-8984, Scheeletorget 1, 223 81 Lund, has December 11, 2025 been declared bankrupt by the District Court of Lund.
The District Court of Lund has appointed lawyer Peter Thörnwall at Wesslau Advokatbyrå as trustee. Peter Törnwall can be reached at +46 (0)42 453 79 01 or peter.thornwall@wadv.se.
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
Kerstin Jakobsson, Chairman
Phone: +46 70 550 45 40
E-mail: kj@diagonalbio.com
About Diagonal Bio
Diagonal Bio offers a point of care testing system for genetic markers that detects pathogens for viruses, bacteria and fungi. The system is approved for use in animals and current target markets are horses, small animals and fish farms. The Company has expertise in developing markers for eLAMP-testing that can be used on Diagonal’s own system or any other platform using LAMP technology, which creates a potential for licensing and partnerships in the future. Diagonal Bio was founded in 2020, is listed on NGM and headquartered in Lund, Sweden.